title: The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma.
abstract: OBJECTIVE
  We performed an investigation of the prognostic significance of the invasive component size, excluding lepidic growth, in lung adenocarcinoma patients.
  
  
  METHODS
  The data from 603 patients with completely resected pathologic stage I lung adenocarcinomas were analyzed retrospectively to determine the relationship between pathologic tumor size and surgical results.
  
  
  RESULTS
  The median tumor size of the total growth and the invasive component were 2.2 cm and 1.3 cm, respectively. There were significant differences in recurrence-free survival between patients classified on the basis of invasive component sizes (≤ 0.5 cm vs 0.5-2.0 cm, P < .001; and 0.5-2.0 cm vs > 2.0 cm; P = .026). A multivariate Cox regression analysis showed that invasive component size (P = .002), age, sex, and lymphatic invasion were independent prognostic factors for recurrence-free survival, whereas total tumor size was not (P = .068). There were no significant differences in recurrence-free survival between patients who received adjuvant chemotherapy and those who did not in the group with invasive component size of 0.5 cm or less (P = .29) and in the group with invasive component size of 0.5 to 2.0 cm (P = .50). However, the recurrence-free survival of patients who received adjuvant chemotherapy was significantly better than that of those who did not in the group with invasive component size greater than 2.0 cm (P = .009).
  
  
  CONCLUSIONS
  Pathologic invasive component size, as opposed to total tumor size, is associated more significantly with malignant behavior and prognosis and specifically should be considered before choosing candidates for adjuvant chemotherapy in pathologic stage I lung adenocarcinoma.
authors.affiliation: Department of Surgical Oncology, Hiroshima University, Hiroshima City, Hiroshima, Japan.
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Tsutani
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Miyata
authors.forename: Takahiro
authors.initials: T
authors.lastname: Mimae
authors.forename: Kei
authors.initials: K
authors.lastname: Kushitani
authors.forename: Yukio
authors.initials: Y
authors.lastname: Takeshima
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yoshimura
authors.forename: Morihito
authors.initials: M
authors.lastname: Okada
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019540:Area Under Curve; D017024:Chemotherapy, Adjuvant; D003661:Decision Support Techniques; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007564:Japan; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D018579:Patient Selection; D011013:Pneumonectomy; D016016:Proportional Hazards Models; D012372:ROC Curve; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D047368:Tumor Burden
keywords: 10; AIS; AUC; CT; LY; MIA; NSCLC; PL; RFS; ROC; V; adenocarcinoma in situ; area under the curve; computed tomography; lymphatic invasion; minimally invasive adenocarcinoma; non–small cell lung cancer; pleural invasion; receiver operating characteristic; recurrence-free survival; vascular invasion